Amevive® (Alefacept) - A - Detailing from Skin Therapy Letter


Amevive® (Alefacept)







  • Alefacept experience in clinical trials and in practice is in moderate to severe psoriasis.
  • Early clinical experience suggests that the optimal use of Alefacept may involve two courses.
  • Some patients have shown benefit from receiving longer courses of therapy (treat to clear) than mandated by the FDA in clinical trials (12 weeks).
  • A washout period is not required when transitioning a patient to Alefacept from another systemic therapy.
  • While the patient is on Alefacept, the dose of the other therapy can be titrated down and then discontinued.
  • Combination therapy has also been used to speed up the onset of Alefacept and provide even longer remissions.

Next:   Indications